Proteins with intrinsically disordered domains are preferentially recruited to polyglutamine aggregates

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Wear, Maggie P ^a   Kryndushkin, Dmitry ^a   O'Meally, Robert ^b   Sonnenberg, Jason L ^c   Cole, Robert N ^b   Shewmaker, Frank P ^a   Nagai, Yoshitaka ^d  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c STEVENSON UNIVERSITY   (United States)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AAK1 PROTEIN; BMH1 PROTEIN; CLINT1 PROTEIN; DDX5 PROTEIN; DEF1 PROTEIN; DNAJA2 PROTEIN; DNAJA4 PROTEIN; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; POLYGLUTAMINE; PROTEIN AGGREGATE; RNA BINDING PROTEIN; RNPA3 PROTEIN; SFN PROTEIN; SGT2 PROTEIN; SGTA PROTEIN; UNCLASSIFIED DRUG; YWHAB PROTEIN; HTT PROTEIN, HUMAN; HUNTINGTIN; NERVE PROTEIN; PEPTIDE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; FUNGAL GENE; GAL1 GENE; GENE EXPRESSION; MASS SPECTROMETRY; NONHUMAN; PC12 CELL LINE; PROMOTER REGION; PROTEIN AGGREGATION; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN RNA BINDING; RAT; REPRODUCIBILITY; SACCHAROMYCES CEREVISIAE; ANIMAL; GENETICS; HUMAN; METABOLISM;

ANIMALS; HUMANS; HUNTINGTIN PROTEIN; NERVE TISSUE PROTEINS; PC12 CELLS; PEPTIDES; PROTEIN AGGREGATES; RATS; RNA-BINDING PROTEINS; SACCHAROMYCES CEREVISIAE;

EID: 84943339574     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136362     Document Type: Article

References (125)

1. Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nature medicine. 2004 Jul; 10 Suppl:S10-7. PMID: 15272267
2. Taylor JP, Hardy J, Fischbeck KH. Toxic proteins in neurodegenerative disease. Science (New York, NY. 2002 Jun 14; 296(5575):1991-5.
3. Baxa U. Structural basis of infectious and non-infectious amyloids. Curr Alzheimer Res. 2008 Jun; 5(3):308-18.
4. Margittai M, Langen R. Fibrils with parallel in-register structure constitute a major class of amyloid fibrils: molecular insights from electron paramagnetic resonance spectroscopy. Quarterly reviews of biophysics. 2008 Nov; 41(3-4):265-97. doi:10.1017/S0033583508004733 PMID: 19079806
5. Shewmaker F, McGlinchey RP, Wickner RB. Structural insights into functional and pathological amyloid. The Journal of biological chemistry. 2011 May 13; 286(19):16533-40. doi:10.1074/jbc.R111. 227108 PMID: 21454545
6. Tycko R. Solid-state NMR studies of amyloid fibril structure. Annual review of physical chemistry. 2011; 62:279-99. doi:10.1146/annurev-physchem-032210-103539 PMID: 21219138
7. Vendruscolo M, Knowles TP, Dobson CM. Protein solubility and protein homeostasis: ageneric view of protein misfolding disorders. Cold Spring Harbor perspectives in biology. 2014 Dec; 3(12).
8. Dong J, Castro CE, Boyce MC, Lang MJ, Lindquist S. Optical trapping with high forces reveals unexpected behaviors of prion fibrils. Nature structural & molecular biology. 2010 Dec; 17(12):1422-30.
9. Kryndushkin D, Pripuzova N, Burnett B, Shewmaker F. Non-targeted identification of prions and amyloid-forming proteins from yeast and mammalian cells. The Journal of biological chemistry. 2013 Sep 20 288(38):27100-11 doi:10.1074/jbc.M113.485359 PMID: 23926098
10. Kryndushkin DS, Alexandrov IM, Ter-Avanesyan MD, Kushnirov VV. Yeast [PSI+] prion aggregates are formed by small Sup35 polymers fragmented by Hsp104. The Journal of biological chemistry. 2003 Dec 5; 278(49):49636-43. PMID: 14507919
11. MacPhee CE, Dobson CM. Chemical dissection and reassembly of amyloid fibrils formed by a peptide fragment of transthyretin. Journal of molecular biology. 2000 Apr 14; 297(5):1203-15. PMID: 10764584
12. Serio TR, Cashikar AG, Kowal AS, Sawicki GJ, Moslehi JJ, Serpell L, et al. Nucleated conformational conversion and the replication of conformational information by a prion determinant. Science (New York, NY. 2000 Aug 25; 289(5483):1317-21.
13. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature. 2002 Apr 4; 416(6880):507-11. PMID: 11932737
14. Hoffner G, Djian P. Monomeric, oligomeric and polymeric proteins in huntington disease and other diseases of polyglutamine expansion. Brain sciences. 2014; 4(1):91-122. doi:10.3390/brainsci4010091 PMID: 24961702
15. Orr HT, Zoghbi HY. Trinucleotide repeat disorders. Annual review of neuroScience. 2007; 30:575-621. PMID: 17417937
16. Nelson DL, Orr HT, Warren ST. The unstable repeats - three evolving faces of neurological disease. Neuron. 2013 Mar 6; 77(5):825-43. doi:10.1016/j.neuron.2013.02.022 PMID: 23473314
17. Scherzinger E, Lurz R, Turmaine M, Mangiarini L, Hollenbach B, Hasenbank R, et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell. 1997 Aug 8; 90(3):549-58. PMID: 9267034
18. Chen S, Berthelier V, Hamilton JB, O'Nuallain B, Wetzel R. Amyloid-like features of polyglutamine aggregates and their assembly kinetics. Biochemistry. 2002 Jun 11; 41(23):7391-9. PMID: 12044172
19. Sieradzan KA, Mechan AO, Jones L, Wanker EE, Nukina N, Mann DM. Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Experimental neurology. 1999 Mar; 156(1):92-9. PMID: 10192780
20. Gourfinkel-An I, Cancel G, Duyckaerts C, Faucheux B, Hauw JJ, Trottier Y, et al. Neuronal distribution of intranuclear inclusions in Huntington's disease with adult onset. Neuroreport. 1998 Jun 1; 9(8):1823-6. PMID: 9665608
21. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 1997 Aug 8; 90(3):537-48. PMID: 9267033
22. Davranche A, Aviolat H, Zeder-Lutz G, Busso D, Altschuh D, Trottier Y, et al. Huntingtin affinity for partners is not changed by polyglutamine length: aggregation itself triggers aberrant interactions. Human molecular genetics. 2011 Jul 15; 20(14):2795-806. doi:10.1093/hmg/ddr178 PMID: 21518730
23. Rubinsztein DC, Carmichael J. Huntington's disease: molecular basis of neurodegeneration. Expert reviews in molecular medicine. 2003 Aug; 5(20):1-21. PMID: 14585171
24. Jacobsen JC, Gregory GC, Woda JM, Thompson MN, Coser KR, Murthy V, et al. HD CAG-correlated gene expression changes support a simple dominant gain of function. Human molecular genetics. 2011 Jul 15; 20(14):2846-60. doi:10.1093/hmg/ddr195 PMID: 21536587
25. Henshall TL, Tucker B, Lumsden AL, Nornes S, Lardelli MT, Richards RI. Selective neuronal requirement for huntingtin in the developing zebrafish. Human molecular genetics. 2009 Dec 15; 18(24):4830-42. doi:10.1093/hmg/ddp455 PMID: 19797250
26. Yang H, Li JJ, Liu S, Zhao J, Jiang YJ, Song AX, et al. Aggregation of polyglutamine-expanded ataxin-3 sequesters its specific interacting partners into inclusions: implication in a loss-of-function pathology. Scientific reports. 2014; 4:6410. doi:10.1038/srep06410 PMID: 25231079
27. Park SH, Kukushkin Y, Gupta R, Chen T, Konagai A, Hipp MS, et al. PolyQ proteins interfere with nuclear degradation of cytosolic proteins by sequestering the Sis1pchaperone. Cell. 2013 Jul 3; 154(1):134-45. doi:10.1016/j.cell.2013.06.003 PMID: 23791384
28. Kryndushkin D, Wear MP, Shewmaker F. Amyloid cannot resist identification. Prion. 2013 Dec 23; 7(6).
29. Li SH, Li XJ. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet. 2004 Mar; 20(3):146-54. PMID: 15036808
30. Harjes P, Wanker EE. The hunt for huntingtin function: interaction partners tell many different stories. Trends in biochemical sciences. 2003 Aug; 28(8):425-33. PMID: 12932731
31. Waelter S, Boeddrich A, Lurz R, Scherzinger E, Lueder G, Lehrach H, et al. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Molecular biology of the cell. 2001 May; 12(5):1393-407. PMID: 11359930
32. Kaltenbach LS, Romero E, Becklin RR, Chettier R, Bell R, Phansalkar A, et al. Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS genetics. 2007 May 11; 3(5):e82. PMID: 17500595
33. Tourette C, Li B, Bell R, O'Hare S, Kaltenbach LS, Mooney SD, et al. A large scale Huntingtin protein interaction network implicates Rho GTPase signaling pathways in Huntington disease. The Journal of biological chemistry. 2014 Mar 7; 289(10):6709-26. doi:10.1074/jbc.M113.523696 PMID: 24407293
34. Uversky VN. Intrinsically disordered proteins and their (disordered) proteomes in neurodegenerative disorders. Frontiers in aging neuroScience. 2015; 7:18. doi:10.3389/fnagi.2015.00018 PMID: 25784874
35. Meriin AB, Zhang X, He X, Newnam GP, Chernoff YO, Sherman MY. Huntington toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1. The Journal of cell biology. 2002 Jun 10; 157(6):997-1004. PMID: 12058016
36. Edskes HK, Wickner RB. Conservation of a portion of the S. cerevisiae Ure2p prion domain that interacts with the full-length protein. Proceedings of the National Academy of Sciences of the United States of America. 2002 Dec 10; 99 Suppl 4:16384-91. PMID: 12177423
37. Edskes HK, Wickner RB. A protein required for prion generation: [URE3] induction requires the Rasregulated Mks1 protein. Proceedings of the National Academy of Sciences of the United States of America. 2000 Jun 6; 97(12):6625-9. PMID: 10823922
38. Kryndushkin D, Wickner RB, Shewmaker F. FUS/TLS forms cytoplasmic aggregates, inhibits cell growth and interacts with TDP-43 in a yeast model of amyotrophic lateral sclerosis. Protein & cell. 2011 Mar; 2(3):223-36.
39. Wyttenbach A, Swartz J, Kita H, Thykjaer T, Carmichael J, Bradley J, et al. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. Human molecular genetics. 2001 Aug 15; 10(17):1829-45. PMID: 11532992
40. Wisniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. Nature methods. 2009 May; 6(5):359-62. doi:10.1038/nmeth.1322 PMID: 19377485
41. Old WM, Meyer-Arendt K, Aveline-Wolf L, Pierce KG, Mendoza A, Sevinsky JR, et al. Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol Cell Proteomics. 2005 Oct; 4(10):1487-502. PMID: 15979981
42. Zybailov B, Mosley AL, Sardiu ME, Coleman MK, Florens L, Washburn MP. Statistical analysis of membrane proteome expression changes in Saccharomyces cerevisiae. Journal of proteome research. 2006 Sep; 5(9):2339-47. PMID: 16944946
43. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nature genetics. 2000 May; 25(1):25-9. PMID: 10802651
44. Cherry JM, Hong EL, Amundsen C, Balakrishnan R, Binkley G, Chan ET, et al. Saccharomyces Genome Database: the genomics resource of budding yeast. Nucleic acids research. 2012 Jan; 40 (Database issue):D700-5. doi:10.1093/nar/gkr1029 PMID: 22110037
45. Laulederkind SJ, Hayman GT, Wang SJ, Smith JR, Lowry TF, Nigam R, et al. The Rat Genome Database 2013 - data, tools and users. Briefings in bioinformatics. 2013 Jul; 14(4):520-6. doi:10.1093/bib/bbt007 PMID: 23434633
46. Michelitsch MD, Weissman JS. A census of glutamine/asparagine-rich regions: implications fortheir conserved function and the prediction of novel prions. Proceedings of the National Academy of Sciences of the United States of America. 2000 Oct 24; 97(22):11910-5. PMID: 11050225
47. Dosztanyi Z, Csizmok V, Tompa P, Simon I. IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content. Bioinformatics (Oxford, England). 2005 Aug 15; 21(16):3433-4.
48. Newman JR, Ghaemmaghami S, Ihmels J, Breslow DK, Noble M, DeRisi JL, et al. Single-cell proteomic analysis of S. cerevisiae reveals the architecture of biological noise. Nature. 2006 Jun 15; 441 (7095):840-6. PMID: 16699522
49. Ghaemmaghami S, Huh WK, Bower K, Howson RW, Belle A, Dephoure N, et al. Global analysis of protein expression in yeast. Nature. 2003 Oct 16; 425(6959):737-41. PMID: 14562106
50. Futcher B, Latter GI, Monardo P, McLaughlin CS, Garrels JI. A sampling of the yeast proteome. Molecular and cellular biology. 1999 Nov; 19(11):7357-68. PMID: 10523624
51. Lu P, Vogel C, Wang R, Yao X, Marcotte EM. Absolute protein expression profiling estimates the relative contributions of transcriptional and translational regulation. Nature biotechnology. 2007 Jan; 25(1):117-24. PMID: 17187058
52. Shewmaker F, Kryndushkin D, Chen B, Tycko R, Wickner RB. Two prion variants of Sup35p have inregister parallel beta-sheet structures, independent of hydration. Biochemistry. 2009 Jun 16; 48(23):5074-82. doi:10.1021/bi900345q PMID: 19408895
53. Schwartz R, Ting CS, King J. Whole proteome pI values correlate with subcellular localizations of proteins for organisms within the three domains of life. Genome research. 2001 May; 11(5):703-9. PMID: 11337469
54. Baltz AG, Munschauer M, Schwanhausser B, Vasile A, Murakawa Y, Schueler M, et al. The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts. Molecular cell. 2012 Jun 8; 46(5):674-90. doi:10.1016/j.molcel.2012.05.021 PMID: 22681889
55. Ramaswami M, Taylor JP, Parker R. Altered ribostasis: RNA-protein granules in degenerative disorders. Cell. 2013 Aug 15; 154(4):727-36. doi:10.1016/j.cell.2013.07.038 PMID: 23953108
56. Furukawa Y, Kaneko K, Matsumoto G, Kurosawa M, Nukina N. Cross-seeding fibrillation of Q/N-rich proteins offers new pathomechanism of polyglutamine diseases. J Neurosci. 2009 Apr 22; 29(16):5153-62. doi:10.1523/JNEUROSCI.0783-09.2009 PMID: 19386911
57. Karlin S, Brocchieri L, Bergman A, Mrazek J, Gentles AJ. Amino acid runs in eukaryotic proteomes and disease associations. Proceedings of the National Academy of Sciences of the United States of America. 2002 Jan 8; 99(1):333-8. PMID: 11782551
58. Ward JJ, McGuffin LJ, Bryson K, Buxton BF, Jones DT. The DISOPRED serverforthe prediction of protein disorder. Bioinformatics (Oxford, England). 2004 Sep 1; 20(13):2138-9.
59. Vucetic S, Xie H, Iakoucheva LM, Oldfield CJ, Dunker AK, Obradovic Z, et al. Functional anthology of intrinsic disorder. 2. Cellular components, domains, technical terms, developmental processes, and coding sequence diversities correlated with long disordered regions. Journal of proteome research. 2007 May; 6(5):1899-916. PMID: 17391015
60. Tompa P, Fuxreiter M, Oldfield CJ, Simon I, Dunker AK, Uversky VN. Close encounters of the third kind: disordered domains and the interactions of proteins. Bioessays. 2009 Mar; 31(3):328-35. doi:10.1002/bies.200800151 PMID: 19260013
61. Duennwald ML, Jagadish S, Giorgini F, Muchowski PJ, Lindquist S. A network of protein interactions determines polyglutamine toxicity. Proceedings of the National Academy of Sciences of the United States of America. 2006 Jul 18; 103(29):11051-6. PMID: 16832049
62. Kiktev DA, Patterson JC, Muller S, Bariar B, Pan T, Chernoff YO. Regulation of chaperone effects on a yeast prion by cochaperone Sgt2. Molecular and cellular biology. 2012 Dec; 32(24):4960-70. doi:10.1128/MCB.00875-12 PMID: 23045389
63. Wang Y, Meriin AB, Zaarur N, Romanova NV, Chernoff YO, Costello CE, et al. Abnormal proteins can form aggresome in yeast: aggresome-targeting signals and components of the machinery. Faseb J. 2009 Feb; 23(2):451-63. doi:10.1096/fj.08-117614 PMID: 18854435
64. Outeiro TF, Lindquist S. Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science (NewYork, NY. 2003 Dec5; 302(5651):1772-5.
65. Mayer MP, Bukau B. Hsp70 chaperones: cellular functions and molecular mechanism. Cell Mol Life Sci. 2005 Mar; 62(6):670-84. PMID: 15770419
66. Bonini NM. Chaperoning brain degeneration. Proceedings of the National Academy of Sciences of the United States of America. 2002 Dec 10; 99 Suppl 4:16407-11. PMID: 12149445
67. Mitsui K, Doi H, Nukina N. Proteomics of polyglutamine aggregates. Methods in enzymology. 2006; 412:63-76. PMID: 17046652
68. Kryndushkin D, Wickner RB, Shewmaker F. FUS/TLS forms cytoplasmic aggregates, inhibits cell growth and interacts with TDP-43 in a yeast model of amyotrophic lateral sclerosis. Protein & cell. 2011 Mar 30.
69. Fushimi K, Long C, Jayaram N, Chen X, Li L, Wu JY. Expression of human FUS/TLS in yeast leads to protein aggregation and cytotoxicity, recapitulating key features of FUS proteinopathy. Protein & cell. 2011 Feb 14; 2(2):141-9
70. Ju S, Tardiff DF, Han H, Divya K, Zhong Q, Maquat LE, et al. Ayeast model of FUS/TLS-dependent cytotoxicity. PLoS biology. 2011 Apr; 9(4):e1001052. doi:10.1371/journal.pbio.1001052 PMID: 21541368
71. Sun Z, Diaz Z, Fang X, Hart MP, Chesi A, Shorter J, et al. Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. PLoS biology. 2011 Apr; 9(4): e1000614. doi:10.1371/journal.pbio.1000614 PMID: 21541367
72. Daigle JG, Lanson NA Jr, Smith RB, Casci I, Maltare A, Monaghan J, et al. RNA-binding ability of FUS regulates neurodegeneration, cytoplasmic mislocalization and incorporation into stress granules associated with FUS carrying ALS-linked mutations. Human molecular genetics. 2013 Mar 15; 22(6):1193-205. doi:10.1093/hmg/dds526 PMID: 23257289
73. Martindale D, Hackam A, Wieczorek A, Ellerby L, Wellington C, McCutcheon K, et al. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nature genetics. 1998 Feb; 18(2):150-4. PMID: 9462744
74. Holbert S, Denghien I, Kiechle T, Rosenblatt A, Wellington C, Hayden MR, et al. The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. Proceedings of the National Academy of Sciences of the United States of America. 2001 Feb 13; 98(4):1811-6. PMID: 11172033
75. Rutherford NJ, Lewis J, Clippinger AK, Thomas MA, Adamson J, Cruz PE, et al. Unbiased screen reveals ubiquilin-1 and-2 highly associated with huntingtin inclusions. Brain research. 2013 Aug 2; 1524:62-73. doi:10.1016/j.brainres.2013.06.006 PMID: 23774650
76. Doi H, Mitsui K, Kurosawa M, Machida Y, Kuroiwa Y, Nukina N. Identification of ubiquitin-interacting proteins in purified polyglutamine aggregates. FEBS letters. 2004 Jul 30; 571(1-3):171-6. PMID: 15280037
77. Wang Y, Meriin AB, Costello CE, Sherman MY. Characterization of proteins associated with polyglutamine aggregates: a novel approach towards isolation of aggregates from protein conformation disorders. Prion. 2007 Apr-Jun; 1(2):128-35. PMID: 19164926
78. Ratovitski T, Chighladze E, Arbez N, Boronina T, Herbrich S, Cole RN, et al. Huntingtin protein interactions altered by polyglutamine expansion as determined by quantitative proteomic analysis. Cell cycle (Georgetown, Tex. 2012 May 15; 11(10):2006-21.
79. Novoselova TV, Margulis BA, Novoselov SS, Sapozhnikov AM, van der Spuy J, Cheetham ME, et al. Treatment with extracellular HSP70/HSC70 protein can reduce polyglutamine toxicity and aggregation. Journal of neurochemistry. 2005 Aug; 94(3):597-606. PMID: 15992387
80. Couthouis J, Hart MP, Shorter J, DeJesus-Hernandez M, Erion R, Oristano R, et al. A yeast functional screen predicts new candidate ALS disease genes. Proceedings of the National Academy of Sciences of the United States of America. 2011 Dec 27; 108(52):20881-90. doi:10.1073/pnas. 1109434108 PMID: 22065782
81. King OD, Gitler AD, Shorter J. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain research. 2012 Jun 26; 1462:61-80. doi:10.1016/j.brainres.2012. 01.016 PMID: 22445064
82. Li YR, King OD, Shorter J, Gitler AD. Stress granules as crucibles of ALS pathogenesis. The Journal of cell biology. 2013 Apr 29; 201(3):361-72. doi:10.1083/jcb.201302044 PMID: 23629963
83. Wiederhold E, Veenhoff LM, Poolman B, Slotboom DJ. Proteomics of Saccharomyces cerevisiae Organelles. Mol Cell Proteomics. 2010 Mar; 9(3):431-45. doi:10.1074/mcp.R900002-MCP200 PMID: 19955081
84. Calvo SE, Mootha VK. The mitochondrial proteome and human disease. Annual review of genomics and human genetics. 2010; 11:25-44. doi:10.1146/annurev-genom-082509-141720 PMID: 20690818
85. Yao J, Ong SE, Bajjalieh S. Huntingtin is associated with cytomatrix proteins at the presynaptic terminal. Molecular and cellular neurosciences. 2014 Nov; 63:96-100. PMID: 25461618
86. Raychaudhuri S, Dey S, Bhattacharyya NP, Mukhopadhyay D. The role of intrinsically unstructured proteins in neurodegenerative diseases. PloS one. 2009; 4(5):e5566. doi:10.1371/journal.pone. 0005566 PMID: 19440375
87. Tompa P, Csermely P. The role of structural disorder in the function of RNA and protein chaperones. Faseb J. 2004 Aug; 18(11):1169-75. PMID: 15284216
88. Ivanyi-Nagy R, Davidovic L, Khandjian EW, Darlix JL. Disordered RNA chaperone proteins: from functions to disease. Cell Mol Life Sci. 2005 Jul; 62(13):1409-17. PMID: 15924259
89. Uversky VN, Gillespie JR, Fink AL. Why are "natively unfolded" proteins unstructured under physiologic conditions? Proteins. 2000 Nov 15; 41(3):415-27. PMID: 11025552
90. Chen-Plotkin AS, Lee VM, Trojanowski JQ. TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol. 2010 Apr; 6(4):211-20.
91. Da Cruz S, Cleveland DW. Understanding the role of TDP-43and FUS/TLS in ALS and beyond. Current opinion in neurobiology. 2011 Dec; 21(6):904-19. doi:10.1016/j.conb.2011.05.029 PMID: 21813273
92. Mackenzie IR, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. The Lancet. 2010 Oct; 9(10):995-1007. doi:10.1016/S1474-4422(10) 70195-2 PMID: 20864052
93. Fuentealba RA, Udan M, Bell S, Wegorzewska I, Shao J, Diamond MI, et al. Interaction with polyglutamine aggregates reveals a Q/N-rich domain in TDP-43. The Journal of biological chemistry. 2010 Aug 20; 285(34):26304-14. doi:10.1074/jbc.M110.125039 PMID: 20554523
94. Jana NR, Tanaka M, Wang G, Nukina N. Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity. Human molecular genetics. 2000 Aug 12; 9(13):2009-18. PMID: 10942430
95. Hands SL, Wyttenbach A. Neurotoxic protein oligomerisation associated with polyglutamine diseases. Acta neuropathologica. 2010 Oct; 120(4):419-37. doi:10.1007/s00401-010-0703-0 PMID: 20514488
96. Sakahira H, Breuer P, Hayer-Hartl MK, Hartl FU. Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity. Proceedings of the National Academy of Sciences of the United States of America. 2002 Dec 10; 99 Suppl 4:16412-8. PMID: 12189209
97. Habchi J, Tompa P, Longhi S, Uversky VN. Introducing protein intrinsic disorder. Chemical reviews. 2014 Jul 9; 114(13):6561-88. doi:10.1021/cr400514h PMID: 24739139
98. Dosztanyi Z, Csizmok V, Tompa P, Simon I. The pairwise energy content estimated from amino acid composition discriminates between folded and intrinsically unstructured proteins. Journal of molecular biology. 2005 Apr 8; 347(4):827-39. PMID: 15769473
99. Castello A, Fischer B, Eichelbaum K, Horos R, Beckmann BM, Strein C, et al. Insights into RNA biology from an atlas of mammalian mRNA-binding proteins. Cell. 2012 Jun 8; 149(6):1393-406. doi:10.1016/j.cell.2012.04.031 PMID: 22658674
100. Shi B, Conner SD, Liu J. Dysfunction of endocytic kinase AAK1 in ALS. International journal of molecular sciences. 2014; 15(12):22918-32. doi:10.3390/ijms151222918 PMID: 25514244
101. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science (New York, NY. 2009 Feb 27; 323(5918):1205-8.
102. Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, Sreedharan J, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science (New York, NY. 2009 Feb 27; 323(5918):1208-11.
103. Doi H, Okamura K, Bauer PO, Furukawa Y, Shimizu H, Kurosawa M, et al. RNA-binding protein TLS is a major nuclear aggregate-interacting protein in huntingtin exon 1 with expanded polyglutamine-expressing cells. The Journal of biological chemistry. 2008 Mar 7; 283(10):6489-500. doi:10.1074/jbc.M705306200 PMID: 18167354
104. Mori K, Lammich S, Mackenzie IR, Forne I, Zilow S, Kretzschmar H, et al. hnRNPA3 binds to GGGGCC repeats and is a constituent of p62-positive/TDP43-negative inclusions in the hippocampus of patients with C9orf72 mutations. Acta neuropathologica. 2013 Mar; 125(3):413-23. doi:10.1007/s00401-013-1088-7 PMID: 23381195
105. Cummings CJ, Mancini MA, Antalffy B, DeFranco DB, Orr HT, Zoghbi HY. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nature genetics. 1998 Jun; 19(2):148-54. PMID: 9620770
106. Johnson JO, Pioro EP, Boehringer A, Chia R, Feit H, Renton AE, et al. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nature neuroScience. 2014 May; 17(5):664-6. doi:10.1038/nn.3688 PMID: 24686783
107. Kim WY, Fayazi Z, Bao X, Higgins D, Kazemi-Esfarjani P. Evidence for sequestration of polyglutamine inclusions by Drosophila myeloid leukemia factor. Molecular and cellular neurosciences. 2005 Aug; 29(4):536-44. PMID: 15936212
108. Shelkovnikova TA, Robinson HK, Troakes C, Ninkina N, Buchman VL. Compromised paraspeckle formation as a pathogenic factor in FUSopathies. Human molecular genetics. 2014 May 1; 23(9):2298-312. doi:10.1093/hmg/ddt622 PMID: 24334610
109. Basso M, Massignan T, Samengo G, Cheroni C, De Biasi S, Salmona M, et al. Insoluble mutant SOD1 is partly oligoubiquitinated in amyotrophic lateral sclerosis mice. The Journal of biological chemistry. 2006 Nov 3; 281(44):33325-35. PMID: 16943203
110. Bergink S, Severijnen LA, Wijgers N, Sugasawa K, Yousaf H, Kros JM, et al. The DNA repair-ubiquitin-associated HR23 proteins are constituents of neuronal inclusions in specific neurodegenerative disorders without hampering DNA repair. Neurobiology of disease. 2006 Sep; 23(3):708-16. PMID: 16860562
111. Wang G, Sawai N, Kotliarova S, Kanazawa I, Nukina N. Ataxin-3, the MJD1 gene product, interacts with the two human homologs of yeast DNA repair protein RAD23, HHR23Aand HHR23B. Human molecular genetics. 2000 Jul 22; 9(12):1795-803. PMID: 10915768
112. Mizuno Y, Amari M, Takatama M, Aizawa H, Mihara B, Okamoto K. Immunoreactivities of p62, an ubiqutin-binding protein, in the spinal anterior horn cells of patients with amyotrophic lateral sclerosis. Journal of the neurological sciences. 2006 Nov 1; 249(1):13-8. PMID: 16820172
113. Kuusisto E, Salminen A, Alafuzoff I. Ubiquitin-binding protein p62is present in neuronal and glial inclusions in human tauopathies and synucleinopathies. Neuroreport. 2001 Jul 20; 12(10):2085-90. PMID: 11447312
114. Zatloukal K, Stumptner C, Fuchsbichler A, Heid H, Schnoelzer M, Kenner L, et al. p62 Is a common component of cytoplasmic inclusions in protein aggregation diseases. The American journal of pathology. 2002 Jan; 160(1):255-63. PMID: 11786419
115. Zhou L, Wang H, Ren H, Hu Q, Ying Z, Wang G. Bcl-2 Decreases the Affinity of SQSTM1/p62 to Poly-Ubiquitin Chains and Suppresses the Aggregation of Misfolded Protein in Neurodegenerative Disease. Molecular neurobiology. 2014 Oct 14.
116. Ramirez A, van der Flier WM, Herold C, Ramonet D, Heilmann S, Lewczuk P, et al. SUCLG2 identified as both a determinator of CSF Abeta1-42 levels and an attenuator of cognitive decline in Alzheimer's disease. Human molecular genetics. 2014 Dec 15; 23(24):6644-58. doi:10.1093/hmg/ddu372 PMID: 25027320
117. O'Rourke JG, Gareau JR, Ochaba J, Song W, Rasko T, Reverter D, et al. SUMO-2and PIAS1 modulate insoluble mutant huntingtin protein accumulation. Cell reports. 2013 Jul 25; 4(2):362-75. doi:10.1016/j.celrep.2013.06.034 PMID: 23871671
118. Niikura T, Kita Y, Abe Y. SUMO3 modification accelerates the aggregation of ALS-linked SOD1 mutants. PloSone. 2014; 9(6):e101080. doi:10.1371/journal.pone.0101080 PMID: 24971881
119. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nature genetics. 2008 May; 40(5):572-4. doi:10.1038/ng.132 PMID: 18372902
120. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science (New York, NY. 2008 Mar 21; 319(5870):1668-72.
121. Yamanaka T, Wong HK, Tosaki A, Bauer PO, Wada K, Kurosawa M, et al. Large-scale RNA interference screening in Mammalian cells identifies novel regulators of mutant huntingtin aggregation. PloS one. 2014; 9(4):e93891. doi:10.1371/journal.pone.0093891 PMID: 24705917
122. Ishiura H, Sako W, Yoshida M, Kawarai T, Tanabe O, Goto J, et al. The TRK-fused gene is mutated in hereditary motor and sensory neuropathy with proximal dominant involvement. American journal of human genetics. 2012 Aug 10; 91(2):320-9. doi:10.1016/j.ajhg.2012.07.014 PMID: 22883144
123. Zainelli GM, Dudek NL, Ross CA, Kim SY, Muma NA. Mutant huntingtin protein: a substrate for transglutaminase 1, 2, and 3. Journal of neuropathology and experimental neurology. 2005 Jan; 64(1):58-65. PMID: 15715085
124. Deng HX, Chen W, Hong ST, Boycott KM, Gorrie GH, Siddique N, et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature. 2011 Sep 8; 477 (7363):211-5. doi:10.1038/nature10353 PMID: 21857683
125. Kawamoto Y, Akiguchi I, Fujimura H, Shirakashi Y, Honjo Y, Sakoda S. 14-3-3 proteins in Lewy bodylike hyaline inclusions in a patient with familial amyotrophic lateral sclerosis with a two-base pair deletion in the Cu/Zn superoxide dismutase (SOD1) gene. Acta neuropathologica. 2005 Aug; 110(2):203-4. PMID: 15973542